LLY
1,023.96
+0.31%↑
JNJ
196.01
+0.34%↑
ABBV
232.37
0%↓
UNH
321.37
-3.25%↓
AZN
89.14
+0.64%↑
LLY
1,023.96
+0.31%↑
JNJ
196.01
+0.34%↑
ABBV
232.37
0%↓
UNH
321.37
-3.25%↓
AZN
89.14
+0.64%↑
LLY
1,023.96
+0.31%↑
JNJ
196.01
+0.34%↑
ABBV
232.37
0%↓
UNH
321.37
-3.25%↓
AZN
89.14
+0.64%↑
LLY
1,023.96
+0.31%↑
JNJ
196.01
+0.34%↑
ABBV
232.37
0%↓
UNH
321.37
-3.25%↓
AZN
89.14
+0.64%↑
LLY
1,023.96
+0.31%↑
JNJ
196.01
+0.34%↑
ABBV
232.37
0%↓
UNH
321.37
-3.25%↓
AZN
89.14
+0.64%↑
24h
Current
Min
7.57
Max
7.75
Income | -73M -99M |
|---|---|
Sales | 9.1M 11M |
Profit margin | -876.339 |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +91.12% upside |
Market Cap | 377M |
|---|---|
Previous open | 14.23 |
Previous close | 7.57 |
Past performance is not a reliable indicator of future results.
8 May 2025, 19:14 UTC
Verastem Ovarian-Cancer Drug Combination Gets FDA Approval -- Update
DJ
Read
31 Dec 2024, 19:15 UTC
Verastem Shares Soar on FDA Priority Review of Cancer Treatment
DJ
Read
Price change
By TipRanks
12 Months Forecast
Average 15.5 USD 91.12%
High 20 USD
Low 14 USD
Based on 7 Wall Street analysts offering 12 month price targets forVerastem Inc - Dist in the last 3 months.
By TipRanks
Strong Buy
7 ratings
7
Buy
0
Hold
0
Sell
Based on 7 analysts giving stock ratings to Verastem Inc - Dist in the past 3 months.
Selling and administration expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$